南方医科大学学报 ›› 2006, Vol. 26 ›› Issue (02): 234-236.

• • 上一篇    下一篇

Herceptin与阿霉素序贯应用对乳腺癌细胞的杀伤效应

谭科; 范义湘; 缪景霞; 吕成伟; 严晓; 罗荣城;   

  1. 南方医科大学南方医院肿瘤中心; 南方医科大学南方医院肿瘤中心 广东广州510515; 广东广州510515;
  • 出版日期:2006-02-20 发布日期:2006-02-20

Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro

TAN Ke, FAN Yi-xiang, MIAO Jing-xia, L(?) Cheng-wei, YAN Xiao, LUO Rong-cheng Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China   

  1. 南方医科大学南方医院肿瘤中心; 南方医科大学南方医院肿瘤中心 广东广州510515; 广东广州510515;
  • Online:2006-02-20 Published:2006-02-20

摘要: 目的探讨Herceptin与阿霉素序贯应用对乳腺癌细胞株的杀伤效应。方法应用Herceptin、阿霉素及二者联合序贯应用于对数生长期的乳腺癌BT-474细胞,光学显微镜下观察各组细胞用药前后细胞形态变化,流式细胞仪检测各组细胞HER-2/neu的表达率、HER-2/neu表达的平均荧光强度及各组细胞的死亡率。结果光学显微镜下各用药组细胞均有不同程度的变暗、细胞碎片增多、细胞外形部分不规则、细胞内颗粒增多;流式细胞仪检测表明各组间细胞 HER-2/neu表达率无显著性差异,但各用药组细胞HER-2/neu表达的平均荧光强度明显低于对照组(P<0.05);流式细胞仪检测表明各用药组细胞的死亡率明显高于对照组,Herceptin后续应用阿霉素组细胞的死亡率明显高于阿霉素后续应用Herceptin组(P<0.05)。结论应用Herceptin后再辅以阿霉素化疗,对乳腺癌细胞杀伤效应最强,为临床乳腺癌生物化疗的序贯应用模式提供了实验依据。 更多还原

Abstract: Objective To observe the killing effect of Herceptin and adriamycin sequentially applied on breast cancer cell line in vitro. Methods BT-474 human breast cancer cells in exponential growth phase were treated with Herceptin alone, adriamycin alone and their sequential administration (Herceptin before adriamycin and vice versa), respectively. Under optical microscope, the morphological changes of the cells were observed before and after drug administration. The expression rate and mean fluorescence intensity (MFI) of HER-2/neu and cell death rate were detected by flow cytometry. Results Microscopically, the cells treated with different protocols all exhibited such changes as darkening and increase of cellular debris with irregular cell morphology. Flow cytometry revealed no significant difference in the expression rate of HER-2/neu in each group before and after treatment, but the MFI of HER-2/neu and death rate of the treated cells were significant different from those of the control group (P<0.05). The cell death rate of Herceptin-pretreated cells was significantly higher than that of adri-amycin-pretreated ones (P<0.05). Conclusion Herceptin pretreatment enhances the killing effect of adriamycin on breast cancer cell line BT-474, which provides experimental evidence for designing clinical sequential biochemothrapy of breast cancer. 

中图分类号: